[Inhibition of 3H-TdR-incorporation in tumor cells after application of cytotoxic drugs as an indicator of therapeutical efficacy (author's transl)].
In 36 Walker-ascites-carcinosarcoma bearing rats the reduction of 3H-TdR-incorporation into tumor cells after cytotoxic treatment as an potential prognostic factor for efficacy of chemotherapy was tested. Twelve rats each were i.p. treated with 1 mg/kg bw. DDP resp. 0.8 mg/kg bw. adriamycin. Twelve rats were injected with 0.2 mg phs. NaCl and served as control. Survival of rats served as criterion of therapeutic efficacy. There was a significant correlation between reduction of 3H-TdR-uptake in tumor cells after cytotoxic therapy and survival.
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D051381:Rats; D013936:Thymidine / Q000378:metabolism*; D014316:Tritium
D014316:Tritium; D004317:Doxorubicin; D002945:Cisplatin; D013936:Thymidine
Hemmung der 3H-TdR-Aufnahme in Tumorzellen nach Zytostatikagabe als Mass therapeutischer Wirksamkeit.